Molecular Biology Reports

, Volume 38, Issue 1, pp 569–576 | Cite as

Angiotensin converting enzyme I/D, angiotensinogen M235T and AT1-R A/C1166 gene polymorphisms in patients with acromegaly

  • Sebahat Turgut
  • Fulya Akın
  • Raziye Akcılar
  • Ceylan Ayada
  • Günfer Turgut


Acromegaly is associated with increased morbidity and mortality related to cardiovascular disease. Hypertension is one of the most common cardiovascular risk factors in acromegalic patients. The aim of this study was to investigate association between the frequencies of angiotensin converting enzyme (ACE) I/D, angiotensinogen (AGT) M235T and the angiotensin II type 1 receptor (AT1-R) A/C1166 gene polymorphisms and some clinical parameters of acromegalic patients. Total of 33 acromegalic patients and 63 controls were enrolled to study. We determined the ACE I/D, AGT M235T and AT1-R A/C1166 gene polymorphisms. Serum insulin, glucose, triglyceride, HDL-cholesterol, LDL-cholesterol, growth hormone and Insulin-like growth factor I (IGF-I) levels of subjects were analyzed. The frequencies of ACE and M235T AGT genotype were not significantly different between control and patients. The distribution of AT1R A/C1166 genotypes was significantly different between patients and control subjects (P = 0.016). None of the three ACE genotypes, DD, ID and II displayed significant difference in acromegalic patients. A significant difference in systolic blood pressure and the serum IGF-I levels among the three AGT genotype, MM, MT and TT genotypes was found in patient group. Individuals with MT genotypes had significantly higher serum IGF-I levels and systolic blood pressure than MM and TT genotype subjects, P < 0.05. In addition, serum triglyceride and HDL levels differed significantly between MM and MT genotypes, P < 0.05. However, systolic blood pressure of patients with CC genotypes was found to be significantly higher than AA genotypes individuals in acromegaly group, P < 0.05. It can be said that the angiotensinojen MT and AT1R CC1166 genotype carriers may have more risk than other genotypes in the development of hypertension in acromegaly.


Acromegaly Angiotensin converting enzyme Angiotensinogen AT1-receptor Polymorphism 


  1. 1.
    Melmed S (1993) Medical management of acromegaly—what and when? Acta Endocrinol 129:13–17PubMedGoogle Scholar
  2. 2.
    Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152CrossRefPubMedGoogle Scholar
  3. 3.
    Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674CrossRefPubMedGoogle Scholar
  4. 4.
    Bondanelli M, Ambrosio MR, Uberti EC (2001) Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4:239–249CrossRefPubMedGoogle Scholar
  5. 5.
    Moller J (2003) Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res 13:55–74CrossRefPubMedGoogle Scholar
  6. 6.
    Feld S, Hirschberg R (1996) Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 17:423–480PubMedGoogle Scholar
  7. 7.
    Lavoie JL, Sigmund CD (2003) Minireview: overview of the renin–angiotensin system––an endocrine and paracrine system. Endocrinology 144:2179–2183CrossRefPubMedGoogle Scholar
  8. 8.
    Jeunemaître X, Soubrier F, Kotelevtsev YV (1992) Molecular basis of human hypertension: role of angiotensinogen. Cell 71:169–180CrossRefPubMedGoogle Scholar
  9. 9.
    Schuster H, Wienker TF, Stremmler U, Noll B, Steinmetz A, Luft FC (1995) An angiotensin-converting enzyme gene variant is associated with acute myocardial infarction in women but not in men. Am J Cardiol 76:601–603CrossRefPubMedGoogle Scholar
  10. 10.
    Holmer SR, Schunkert H (1996) Adaptive and genetic alterations of the renin angiotensin system in cardiac hypertrophy and failure. Basic Res Cardiol 91:65–71CrossRefPubMedGoogle Scholar
  11. 11.
    Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343–1346CrossRefPubMedGoogle Scholar
  12. 12.
    Turgut G, Turgut S, Genc O, Atalay A, Atalay EO (2004) The angiotensin converting enzyme I/D polymorphism in Turkish athletes and sedentary controls. Acta Medica 47:133–136PubMedGoogle Scholar
  13. 13.
    Sabbagh AS, Otrock ZK, Mahfoud ZR, Zaatari GS, Mahfouz RA (2007) Angiotensin-converting enzyme gene polymorphism and allele frequencies in the Lebanese population: prevalence and review of the literature. Mol Biol Rep 34(1):47–52CrossRefPubMedGoogle Scholar
  14. 14.
    Renner W, Nauck M, Winkelmann BR (2005) Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen risk and cardiovascular health study. J Mol Med 83:235–239CrossRefPubMedGoogle Scholar
  15. 15.
    van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M, Crijns HJ, van Gilst WH (2000) Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 35:717–721PubMedGoogle Scholar
  16. 16.
    Freda PU (2003) Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 13:171–184CrossRefPubMedGoogle Scholar
  17. 17.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMedGoogle Scholar
  18. 18.
    Lebovitz HE (2002) Insulin resistance and the insulin resistance syndrome. In: Clinician’s manual on insulin resistance. Science Press, London, pp 1–15Google Scholar
  19. 19.
    Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F (1992) Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51:197–205PubMedGoogle Scholar
  20. 20.
    Russ AP, Maerz W, Ruzicka V, Stein U, Gross W (1993) Rapid detection of the hypertension-associated Met235-Thr allele of the human angiotensinogen gene. Hum Mol Genet 2:609–610CrossRefPubMedGoogle Scholar
  21. 21.
    Rice T, Rankinen T, Province MA, Chagnon YC, Perusse L, Borecki IB, Bouchard C, Rao DC (2000) Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study. Circulation 102:1956–1963PubMedGoogle Scholar
  22. 22.
    Uemura K, Nakura J, Kohara K, Miki T (2000) Association of ACE I/D polymorphism with cardiovascular risk factors. Hum Genet 107:239–242CrossRefPubMedGoogle Scholar
  23. 23.
    Erbas T, Alikasifoglu M, Aksoyek S, Unsal I, Gedik O, Tuncbilek E (1999) Effects of angiotensin-converting enzyme gene polymorphism on the left-ventricular function and mass in patients with acromegaly. Cardiology 92:226–231CrossRefPubMedGoogle Scholar
  24. 24.
    Mulatero P, Veglio F, Maffei P, Bondanelli M, Bovio S, Daffara F, Leotta G, Angeli A, Calvo C, Martini C, degli Uberti EC, Terzolo M (2006) CYP11B2-344T/C gene polymorphism and blood pressure in patients with acromegaly. J Clin Endocrinol Metab 91:5008–5012CrossRefPubMedGoogle Scholar
  25. 25.
    Akin F, Turgut S, Dursunoglu D, Turgut G, Karasu U, Gur S (2009) ACE gene polymorphism and cardiac structure in patients with insulin resistance. Mol Biol Rep 36(4):623–629CrossRefPubMedGoogle Scholar
  26. 26.
    Menard J, El Amrani AK, Savoie F, Bouhnik J (1991) Angiotensinogen: an attractive but underrated participant in hypertension and inflammation. Hypertension 18:705–706PubMedGoogle Scholar
  27. 27.
    Schmidt S, Sharma AM, Zilch O, Beige J, Walla-Friedel M, Ganten D, Distler A, Ritz E (1995) Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. Nephrol Dial Transplant 10:1145–1148PubMedGoogle Scholar
  28. 28.
    Hegele RA, Harris SB, Hanley AJ, Sun F, Conelly PW, Zinman B (1997) Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. Hypertension 29:1073–1077PubMedGoogle Scholar
  29. 29.
    Fornage M, Turner ST, Sing CF, Boerwinkle E (1995) Variation at the M235T locus of the angiotensinogen gene and essential hypertension, a population-based case-control study from Rochester. Minnesota. Hum Genet 96:295–300Google Scholar
  30. 30.
    Bloem LJ, Foroud TM, Ambrosius WT, Hanna MP, Tewksbury DA, Pratt JH (1997) Association of the angiotensinogen gene to serum angiotensinogen in blacks and whites. Hypertension 29:1078–1082PubMedGoogle Scholar
  31. 31.
    Rotimi C, Morrison L, Cooper R, Oyejide C, Effiong E, Ladipo M, Osotemihen B, Ward R (1994) Angiotensinogen gene in human hypertension. Lack of an association of the T235 allele among the African Americans. Hypertension 24:591–594PubMedGoogle Scholar
  32. 32.
    Nishiuma S, Kario K, Kayaba K, Nagio N, Shimada K, Matsuo T, Matsuo M (1995) Effect of the angiotensinogen gene Met235 → Thr variant on blood pressure and other cardiovascular risk factors in two Japanese populations. J Hypertens 13:717–722CrossRefPubMedGoogle Scholar
  33. 33.
    Iwai N, Shimoike H, Ohmichi N, Kinoshita M (1995) Angiotensinogen gene and blood pressure in the Japanese population. Hypertension 25:688–693PubMedGoogle Scholar
  34. 34.
    Kamide K, Hori MT, Zhu JH, Takagawa Y, Barrett JD, Eggena P, Tuck ML (2000) Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 18:1051–1056CrossRefPubMedGoogle Scholar
  35. 35.
    Wickman A, Friberg P, Adams MA, Matejka GL, Brantsing C, Guron G, Isgaard J (1997) Induction of growth hormone receptor and insulin-like growth factor-I mRNA in aorta and caval vein during hemodynamic challenge. Hypertension 29:123–130PubMedGoogle Scholar
  36. 36.
    Lurbe E, Torro I, Aguilar F, Alvarez J, Alcon J, Pascual JM, Redon J (2008) Added impact of obesity and insulin resistance in nocturnal blood pressure evaluation in children and adolescents. Hypertension 51:635–641CrossRefPubMedGoogle Scholar
  37. 37.
    Sinaiko AR, Steinberger J, Moran A, Hong CP, Prineas RJ, Jacobs DR Jr (2006) Influence of insulin resistance and body mass index at age 13 on systolic blood pressure, triglycerides, and high-density lipoprotein cholesterol at age 19. Hypertension 48:730–736CrossRefPubMedGoogle Scholar
  38. 38.
    Whaley-Connell A, Sowers JR (2008) Obesity, insulin resistance, and nocturnal systolic blood pressure. Hypertension 51(3):635–641CrossRefGoogle Scholar
  39. 39.
    Strufaldi MW, da Silva EM, Puccini RF (2009) Insulin resistance among Brazilian schoolchildren: association with risk factors for cardiovascular diseases. Acta Paediatr Jun 30 [Epub ahead of print]Google Scholar
  40. 40.
    Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E (2000) LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 151:551–557CrossRefPubMedGoogle Scholar
  41. 41.
    Clayton RN (2003) Cardiovascular function in acromegaly. Endocr Rev 24:272–277CrossRefPubMedGoogle Scholar
  42. 42.
    Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F (1994) Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24(1):63–69PubMedGoogle Scholar
  43. 43.
    Castellano M, Muiesan ML, Beschi M, Rizzoni D, Cinelli A, Salvetti M, Pasini G, Porteri E, Bettoni G, Zulli R, Agabiti-Rosei E (1996) Angiotensin II type 1 receptor A/C1166 polymorphism. Relationships with blood pressure and cardiovascular structure. Hypertension 28(6):1076–1080PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Sebahat Turgut
    • 1
  • Fulya Akın
    • 2
  • Raziye Akcılar
    • 1
  • Ceylan Ayada
    • 1
  • Günfer Turgut
    • 1
  1. 1.Department of Physiology, Faculty of MedicineUniversity of PamukkaleDenizliTurkey
  2. 2.Division of Endocrinology, Department of Internal Medicine, Faculty of MedicineUniversity of PamukkaleDenizliTurkey

Personalised recommendations